Saudi Healthtech Biosapien Extends Pre-Series A Round to $8 Million with Globivest Investment
Biosapien, a Saudi Arabian healthtech startup focused on remote patient monitoring, has successfully extended its Pre-Series A funding round, bringing the total raised to $8 million. The round includes new investor Globivest joining a powerful group of existing backers.
A Focus on Remote Care for Chronic Disease in MENA
The Saudi-based startup is dedicated to revolutionizing chronic disease management in the MENA region. Biosapien develops and implements innovative digital solutions that empower both patients and healthcare providers through remote patient monitoring (RPM). Their platform facilitates continuous monitoring and personalized care plans, addressing a critical need to improve health outcomes and reduce healthcare costs associated with chronic conditions.
Backed by a Powerhouse of Saudi and Regional Investors
This funding extension highlights strong and continued investor confidence in Biosapien's model. The company is notably backed by prominent Saudi investors, including Wa'ed Ventures, the venture capital arm of Saudi Aramco, and the Saudi Aramco Entrepreneurship Center. The addition of Globivest to this list further strengthens the company's position and validates its approach to tackling regional healthcare challenges.
About Biosapien
Founded by Jassim Al-Saeed, Biosapien is a health technology company headquartered in Saudi Arabia. Its mission is to leverage technology to create a more connected and proactive healthcare system for patients with chronic diseases across the Middle East and North Africa.
Looking Ahead
With the extended Pre-Series A funding secured, Biosapien is well-positioned for its next phase of growth. The capital infusion will be crucial for enhancing its remote monitoring capabilities, expanding its team, and scaling its operations across key markets in the MENA region, solidifying its role as a leader in Saudi Arabia's burgeoning healthtech sector.
Source: Wamda